Key Takeaways:
Loyal's LOY-002 has cleared two of three FDA technical sections required for Expanded Conditional Approval: Reasonable Expectation of Effectiveness in February 2025 and Target Animal Safety in January 2026. Manufacturing remains the final gate.
The STAY study, Loyal's pivotal efficacy trial, completed enrollment of 1,300 dogs across 70 veterinary clinics nationwide in July 2025, making it the largest clinical trial in the history of veterinary medicine.
If approved, LOY-002 would be the first FDA-approved drug intended to extend healthy lifespan in any species. Loyal has raised over $150 million across funding rounds including a $22 million B-2 led by Valor Equity Partners and Collaborative Fund.
LOY-002 is a daily beef-flavored pill for dogs aged 10 years and older weighing at least 14 pounds. It works as a caloric restriction mimetic, delivering some of the metabolic benefits of severe caloric restriction without requiring dogs to lose weight or suppress appetite.
"Arthritis and cancer and cognitive dysfunction are all different things," Loyal's director of veterinary medicine Brennen McKenzie told Fortune. "But really, aging and metabolic health is one aspect of that that drives all these different things. If we can pick off the underlying driver for all of these things, we can have a much greater impact."
The STAY study is a randomized, double-blinded, placebo-controlled trial in which half of the 1,300 enrolled dogs receive LOY-002 and half receive an identical beef-flavored placebo. It is designed to run a minimum of four years and is measuring lifespan, frailty, quality of life, and age-related disease incidence. Veterinarians at 70 independent clinics, many of them clinical-trial-naive, are collecting data.
"When we said we're going to enroll 1,000 dogs, everybody said, 'You're nuts. There's never been a study that size. It won't happen,'" McKenzie said. In the end, over 12,000 people emailed Loyal wanting to enroll. Loyal expanded the study to 1,300 dogs to increase statistical power.
The FDA's Center for Veterinary Medicine accepted the Reasonable Expectation of Effectiveness section in February 2025 and the Target Animal Safety section in January 2026. The safety review included supplemental field safety data from 400 dogs in the STAY study and found no clinically significant adverse events even at doses five times the intended strength. Manufacturing is the final technical section.
"Since founding Loyal six years ago, my goal has always been to get the first drug FDA approved for lifespan extension," said CEO Celine Halioua. "This safety acceptance brings us very close to achieving that vision."
The shortest path to an FDA-approved human longevity drug might run through a veterinary clinic. The same IGF-1 pathway implicated in large-dog aging shows up across mammals, and the regulatory framework Loyal has built could compress the timeline for human trials that would otherwise take a decade.
Worth watching.
People Also Ask
Q: What is LOY-002? A: LOY-002 is a daily beef-flavored prescription pill developed by Loyal for dogs aged 10 years and older weighing at least 14 pounds. It works as a caloric restriction mimetic, targeting age-related metabolic dysfunction to extend healthy lifespan without requiring dietary restriction.
Q: What is a caloric restriction mimetic? A: A caloric restriction mimetic is a drug that produces the metabolic and longevity benefits of severe caloric restriction without actually reducing caloric intake. Decades of animal research have shown that reduced-calorie diets extend lifespan; LOY-002 aims to trigger the same cellular effects pharmacologically.
Q: When will LOY-002 be available for dogs? A: LOY-002 has cleared two of three FDA technical sections required for Expanded Conditional Approval. Loyal is working to complete the remaining manufacturing section. Conditional approval would allow veterinarians to prescribe the drug while the STAY study continues gathering long-term effectiveness data.
Q: Could LOY-002 lead to longevity drugs for humans? A: Loyal's LOY-002 targets the same IGF-1 pathway that shows up in mammalian aging across species. If the regulatory model and clinical results hold, the STAY study framework could compress the timeline for human longevity trials that have historically faced slow regulatory acceptance.
Sources and Related Reading:
dvm360: Clinical trial for longevity drug meets goal of enrolling 1,000 dogs
Business Wire: Loyal Receives FDA Acceptance of Reasonable Expectation of Effectiveness
WYDE: Anthropic Acquires Stealth Biotech Startup Coefficient Bio
WYDE: RFK Jr. Launches $144 Million Program to Detect and Remove Microplastics